This page is educational. The three-peptide blend has not been formally studied in humans, so its safety profile is inferred from the components, not measured.
The short answer
No controlled safety data exist for this blend — or for any of its three components as injectable products in humans. Anecdotally reported effects are mostly mild and local: injection-site redness or stinging (frequently mentioned with GHK-Cu-containing blends), plus nonspecific headache, fatigue, or nausea. The substantive concerns are structural rather than anecdotal: two components whose central mechanism is promoting blood-vessel growth, a third whose safety record was built topically rather than by injection, an FDA safety-risk flag on BPC-157, and a three-way mixture that makes any reaction impossible to attribute.
Component-level considerations
Injection-site reactions — redness, stinging, irritation — are the most consistently reported issue for injected peptide blends generally.
Angiogenesis-related theoretical risk. Thymosin β4 biology centers on cell migration and new blood-vessel formation (Goldstein et al., Expert Opin Biol Ther 2012), and a 2025 review flags BPC-157's stimulation of angiogenesis and nitric-oxide pathways as a specific, poorly understood risk in humans (Józwiak et al., Pharmaceuticals 2025). Promoting vessel growth is not desirable in every physiological context — tumor biology being the obvious one — and this blend combines two agents selected for exactly that action.
Unknown interactions with medications and conditions; nothing about this mixture has been studied in any population.
The injected copper-peptide question
GHK-Cu is the component people assume is safest, because it is common in cosmetics. But its safety record was built with creams: the comprehensive 2018 review of GHK-Cu's regenerative actions documents cell-culture, animal, and topical human studies — 12-week cosmetic cream trials — and no human injection trials at all (Pickart & Margolina, Int J Mol Sci 2018). Skin-barrier exposure and subcutaneous injection are different toxicology questions, and a copper-complexed peptide injected repeatedly raises copper-handling questions the topical literature was never designed to answer. "Safe in face cream" is not evidence of "safe in a syringe."
Regulatory and anti-doping status
None of the three peptides is an approved medicine anywhere. BPC-157 has been specifically reviewed by the FDA for compounding and placed on its list of substances that may present significant safety risks, with the agency noting immunogenicity concerns and that it "lacks sufficient information to know whether the drug would cause harm when administered to humans" (FDA). For athletes, TB-500 is named in category S2.3 of the WADA Prohibited List (prohibited at all times), and BPC-157 is captured by the S0 non-approved-substances category — so this blend carries doping sanction risk twice over.
Three peptides, one vial
With three actives in one solution, an adverse reaction cannot be pinned on a component, doses cannot be adjusted independently, and the mixture's chemical stability — three structurally unrelated peptides, one of them carrying a redox-active copper ion — has never been characterized. Layer on the usual research-chemical variables (unverified purity, actual peptide content, sterility, endotoxins) and the practical risk of a "GLOW" vial is dominated by what nobody has measured. Component-level safety detail lives on the BPC-157, TB-500, and GHK-Cu side-effect pages.
Sport & Anti-Doping Warning
This combination includes TB-500 and BPC-157, both of which are prohibited in sport; adding GHK-Cu does not change their anti-doping status and can increase the experimental nature of the stack.
Anti-doping rules focus on the presence of any prohibited substance, so a multi-peptide vial that contains BPC-157 or TB-500 still triggers violations.